Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale

por Yassin, Sayf A, Aroda, Vanita R
Publicado 2017

Metformin and Type 2 Diabetes Prevention

por Aroda, Vanita R., Ratner, Robert E.
Publicado 2018

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment

por Aroda, Vanita R., Eckel, Robert H.
Publicado 2022

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

por Aroda, Vanita R., Blonde, Lawrence, Pratley, Richard E.
Publicado 2022

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

por Aroda, Vanita R., Arulandu, Joseph R., Cannon, Anthony J.
Publicado 2018

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences

por Horowitz, Michael, Aroda, Vanita R., Han, Jenny, Hardy, Elise, Rayner, Chris K.
Publicado 2017

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L

por Zisman, Ariel, Dex, Terry, Roberts, Michelle, Saremi, Aramesh, Chao, Jason, Aroda, Vanita R.
Publicado 2018

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L

por Blonde, Lawrence, Berard, Lori, Saremi, Aramesh, Huang, Yao, Aroda, Vanita R., Raccah, Denis
Publicado 2020

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

por Aroda, Vanita R., Faurby, Mads, Lophaven, Søren, Noone, Josh, Wolden, Michael Lyng, Lingvay, Ildiko
Publicado 2021

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

por Aroda, Vanita R., Saugstrup, Trine, Buse, John B., Donsmark, Morten, Zacho, Jeppe, Davies, Melanie J.
Publicado 2019

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan‐L study

por Morea, Nicola, Retnakaran, Ravi, Vidal, Josep, Aroda, Vanita R., Liu, Minzhi, Saremi, Aramesh, Giorgino, Francesco
Publicado 2020

More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc t...

por Frias, Juan, Puig Domingo, Manuel, Meneghini, Luigi, Napoli, Raffaele, Liu, Minzhi, Soltes Rak, Erika, Aroda, Vanita R.
Publicado 2018

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a...

por Sesti, Giorgio, Bardtrum, Lars, Dagdelen, Selcuk, Halladin, Natalie, Haluzík, Martin, Őrsy, Petra, Rodríguez, Martin, Aroda, Vanita R.
Publicado 2020

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses

por Pratley, Richard E, Aroda, Vanita R, Catarig, Andrei-Mircea, Lingvay, Ildiko, Lüdemann, Jörg, Yildirim, Emre, Viljoen, Adie
Publicado 2020

Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus:...

por Rayner, Christopher K., Wu, Tongzhi, Aroda, Vanita R., Whittington, Craig, Kanters, Steve, Guyot, Patricia, Shaunik, Alka, Horowitz, Michael
Publicado 2020

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial...

por Rosenstock, Julio, Blonde, Lawrence, Aroda, Vanita R., Frias, Juan, Souhami, Elisabeth, Ji, Chen, Niemoeller, Elisabeth, Del Prato, Stefano
Publicado 2021

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme

por Aroda, Vanita R., Bauer, Robert, Christiansen, Erik, Haluzík, Martin, Kallenbach, Klaus, Montanya, Eduard, Rosenstock, Julio, Meier, Juris J.
Publicado 2022

Skin Intrinsic Fluorescence Correlates With Autonomic and Distal Symmetrical Polyneuropathy in Individuals With Type 1 Diabetes

por Conway, Baqiyyah N., Aroda, Vanita R., Maynard, John D., Matter, Nathaniel, Fernandez, Stephen, Ratner, Robert E., Orchard, Trevor J.
Publicado 2011

Skin Intrinsic Fluorescence Is Associated With Coronary Artery Disease in Individuals With Long Duration of Type 1 Diabetes

por Conway, Baqiyyah N., Aroda, Vanita R., Maynard, John D., Matter, Nathaniel, Fernandez, Stephen, Ratner, Robert E., Orchard, Trevor J.
Publicado 2012

Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohort

por Kashyap, Sangeeta R., Desouza, Cyrus, Aroda, Vanita R., Kim, Sun H., Neff, Lisa M., Wu, Shannon S., Raskin, Philip, Pratley, Richard
Publicado 2023